Peter. you, Thank
Medicine recall, Baylor sponsored on studies AML from you lead we various selected our cancers, the data academic College based spanning As liquid at solid as collected of or and indication. BCM, tumor
T with trials, February, no In about the In what to our will therapy to which safety will initiate be more demonstrated portion, were we than durable lasting minimal novel cell some patients toxicities. first X responses, five beginning a treated enroll with with lead-in years, company-sponsored by patients. trial, related treatment cleared BCM MultiTAA-specific FDA our the
would legacy safety manufactured reagent, a with were protocol, the using new X from X MultiTAA-specific dosed our supplier. a while in to amended the trial an product reagent patients cell be be alternative Under our remaining with T lead-in first an patients MT-XXX, cleared dosed
reagent the alternate supplier. certificate of on Our partial and the for new by be and clinical accepts analysis reviews hold the to the data remains new final trial until provided FDA the
to latter GMP COVID-XX safety the get facilities, eager Medicine’s patients the Research surrounding our the closed While of College and to currently precautions enrolled X we supply are utilize to in remained we study pandemic. which Baylor study, produce X Phase drug of first due
the study. for and closed need enrollment to the this of portion half we year, into Manufacturing Baylor well pause facilities of remain second patient the But may Research safety the lead-in be at We facility that the interest. become we there time but to – available, will Baylor’s we’re open patient were are study, this able optimistic uncertain once significant will remain when
be Also with has to the delayed the the the providing will due communication in us as pandemic lifting close provide them notified FDA’s and partial information become new with to We that reagent along it satisfy or the requirements updates supplier for remain available. we’ll hold. it
identifying study build related capabilities. interim, to of we the and experiments our out an initiation process own IND required continue also our working sites for In active development and remain the clinical complete to the manufacturing trial of
AML, people and with moving new affects are United of the XX,XXX therapies more alone. sense in which than a States as improved in urgency need for We we recognize
Despite in confident adjustments a therapy. of potential T to our remain the guidance, MultiTAA-specific cell we
granted In a several indicator candidate FDA we lead the orphan in weeks drug just is which designation to disease. our MT-XXX, yet post-transplant challenging ago, for AML strong drug of promise patients to believe with its treat another fact,
demonstrates consistently which antigens, to approaches, have over tumor to cells may T therapies in we more standard may anti-tumor development T sponsored potential As other MultiTAA-specific and epitope MultiTAA-specific as well Because several T potent and across a studies multiple enable seen multiple as recognize types. cell cell their advantages lead therapy of response. BCM durable spreading,
the indications, administered the in evaluating to currently trial whole. which system To setting, in more and addition beneficial is patient, that safer X outpatient patients. AML MultiTAA-specific for post-transplant but not convenient our contrast to in in a other to planned it’s as cells end, require Also, healthcare an hospital transplants, we and opportunities only T stays, Phase which are are
MultiTAA-specific solid for MultiTAA-specific being conducted trials data as AML, results We’ve interim Phase therapy of treatment cancer. other adenocarcinoma cell pancreatic Beyond BCM. reported previously ongoing for X/X the has including therapy cell clinical such an demonstrated early T encouraging pancreatic by T in various tumors cancers,
correlated the TAAs, tumor-reactive release chemotherapy, of in observed blood. indicating observe the a in exhibited combination both treatment or cell And syndrome post-infusion any this antigen against detection targeted spreading. antigens non-targeted have cytokine and T neurotoxicity benefit we cells peripheral in arm of with induction not front-line with standard-of-care the trial. T patient’s clinical These we activity To-date,
for later the as we COVID-XX be which this held Oncology on Meeting Society around available Annual this study at which of will you pandemic. of forward the XXth, to presented will be Clinical update being An know, during virtually detail. will month, on look year account point of this the American Wednesday, ASCO to the May in website, PM X be The abstracts further Eastern able the discuss
after turn to that With questions. to it that, over I look to review we taking financials. forward the will And your Tony
